Published online Jan 18, 2023. doi: 10.5312/wjo.v14.i1.23
Peer-review started: September 14, 2022
First decision: October 17, 2022
Revised: October 20, 2022
Accepted: December 13, 2022
Article in press: December 13, 2022
Published online: January 18, 2023
Processing time: 121 Days and 2.4 Hours
Mesenchymal stromal cell (MSC)-based therapies are being commonly utilized in the context of knee osteoarthritis (OA) with promising results. The commonly used sources of the MSC remain in the bone marrow (BM) and the adipose derived (AD).
Despite the prevalence of the use of MSCs of varying origins in the management of knee OA, the literature is not clear on the ideal source to focus on for future research.
In this study, we aim to compare the efficacy and safety of the two commonly used sources of MSCs namely BM and adipose tissue in the management of knee OA.
We conducted a systematic review and meta-analysis of the randomized controlled trials (RCTs) in the literature identified from databases such as PubMed, EMBASE, Web of Science, and Cochrane Library until August 2021 that analyzed the efficacy and safety of AD and BM-MSCs in the management of knee OA. we used outcome parameters such as the visual analog scale (VAS) score for pain, Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), Lysholm score, Tegner score, magnetic resonance observation of cartilage repair tissue (MOCART) score, knee osteoarthritis outcome score (KOOS), and adverse events.
We identified twenty-one studies including 936 patients. Of all the studies included, only one study compared the two MSC sources without patient randomization; hence, the results of all included studies from both sources were pooled, and a comparative critical analysis was performed. At six months, both AD-MSCs and BM-MSCs showed significant VAS improvement (P = 0.015, P = 0.012); this was inconsistent at 1 year for BM-MSCs (P < 0.001, P = 0.539), and AD-MSCs outperformed BM-MSCs compared to controls in measures such as WOMAC (P < 0.001, P = 0.541), Lysholm scores (P = 0.006; P = 0.933), and KOOS (P = 0.002; P = 0.012). BM-MSC-related procedures caused significant adverse events (P = 0.003) compared to AD-MSCs (P = 0.673).
Our study identified adipose tissue to be superior to BM in terms of its safety and consistent efficacy in improving the pain and functional outcome parameters analyzed.
We suggest for future RCTs be conducted to make a direct comparison of the two sources considering the paucity of the literature identified in this study and also to validate the findings arrived in the study.